Metraipolis › archive › dc_ba01f06eaab9

Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review — Europe PMC PMID:42484063

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42484063
DOI: 10.1002/cam4.72129
License (as archived): solo-consultazione
Archived: 2026-10-18T12:29:25.056Z
SHA-256 of the archived text: af117c12c63a7d0cc69a182eb88fcb580d33bce8b2c3324496fffb3392a8bb76
Stable URL of this page: https://metraipolis.com/documento/dc_ba01f06eaab9

How to cite

Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review — Europe PMC PMID:42484063 — Europe PMC (en), https://europepmc.org/article/MED/42484063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ba01f06eaab9 (Metraipolis archive dc_ba01f06eaab9, sha256 af117c12c63a7d0cc69a182eb88fcb580d33bce8b2c3324496fffb3392a8bb76)

BibTeX

@misc{dcba01f06eaab9,
  title = {Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review — Europe PMC PMID:42484063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42484063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ba01f06eaab9; sha256 af117c12c63a7d0cc69a182eb88fcb580d33bce8b2c3324496fffb3392a8bb76},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42484063. Agents can read the archived copy with the MCP tool read_document.